HQ Team
January 18, 2023: Glenmark Pharmaceuticals, an Indian multinational firm, has introduced its heart failure drug in the country, according to a company statement.
Sacu V, to be taken twice daily, helps patients to reduce cardiovascular deaths and hospitalisation for patients with chronic heart failure.
“Heart failure is growing in India at an alarming rate; its prevalence is about 1% and affects around 8-10 million individuals,” said Alok Malik, EVP & Business Head ‐ India Formulations of Glenmark Pharmaceuticals.
The drug also helps improve heart failure symptoms with reduced ejection fraction, HFrEF.
HFrEF occurs when the left ventricular ejection fraction is 40% or less and succeeded by progressive left ventricular dilatation and adverse cardiac remodelling.
Limitation of physical activity
The patient suffers from the marked limitation of physical activity and is comfortable at rest. They experience less than ordinary activity, causing fatigue, palpitation, dyspnea or shortness of breath.
According to the statement, the tablet, a combination of sacubitril and valsartan, brings down the cost of treatment for heart failure.
“These molecules have two therapeutic targets in the treatment of heart failure: the natriuretic peptide system for sacubitril and the renin-angiotensin system for valsartan.”
A natriuretic peptide is a peptide that induces natriuresis, which is the excretion of sodium by the kidneys. The renin-angiotensin-aldosterone system is a critical regulator of blood volume and systemic vascular resistance.
The renin-angiotensin-aldosterone system may elevate arterial pressure in response to decreased renal blood pressure, reduced salt delivery to the distal convoluted tubule, and beta-agonism. Through these mechanisms, the body can elevate blood pressure in a prolonged manner.
The sacubitril-valsartan combination has an established role in treating patients with heart failure with reduced ejection fraction. The latest heart failure treatment guidelines in Europe and the USA have endorsed it.
INR 19 for 50 mg
Glenmark’s Sacu V is priced at INR 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), INR 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and INR 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103mg).
According to IQVIA sales data for the 12 months ending December 2022, the total cardiology market may be INR 20,7. 30 billion, with an annual growth of 7.7% against last year’s corresponding period.
The ARNI market (sacubitril + valsartan) is estimated to be INR 5,140 million, with an annual growth of 37.2%.
